Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR beta chain-directed selective dual T-cell activator

Authors: Angstadt, Shantel; Horn, Lucas A; Fousek, Kristen; Rajabian, Nika; Qin, Haiyan; Medina-Enriquez, Miriam M; Kelly, Marcus D; Hsiao-Sanchez, Nicole; Meyer, Thomas J; Moisan, Jacques; Katragadda, Madan; Bayliffe, Andrew; Su, Zhen; Schlom, Jeffrey; Palena, Claudia

Source journal: Journal of experimental & clinical cancer research : CR (2026-08-28)

DOI: 10.1186/s13046-026-03815-2

Abstract

BACKGROUND: Resistance to immune checkpoint inhibition (ICI) using antibodies against the PD-1/PD-L1 axis remains a significant clinical challenge. Here, we report that combination of anti-PD-1 with a bifunctional fusion molecule, anti-TCRbeta-IL-2, comprised of a monovalent Fab that binds and activates the T-cell receptor (TCR) through distinct variable beta (Vbeta) chain residues and an IL-2 molecule, mediates robust anti-tumor control in the context of ICI resistance. METHODS: Syngeneic murine models with varying levels of ICI-resistance were used to assess sensitization to ICI in combination with the anti-TCRbeta-IL-2 therapy. Mechanisms of the combination therapy's benefit were investigated by profiling tumor-infiltrating lymphocytes via flow cytometric, single cell transcriptomic, and histological analyses. Immune response efficacy and diversification was identified by the generation of multifunctional, tumor-associated antigen-specific and neoantigen-specific T-cell responses post-therapy. RESULTS: Unlike anti-PD-1 therapy alone that resulted in expansion of terminally exhausted CD8(+) T cells and lack of anti-tumor effect, administration of anti-TCRbeta-IL-2 followed by anti-PD-1 greatly enhanced anti-tumor efficacy leading to tumor cures and long-term protection in several murine models resistant to ICI. Analysis of tumor-infiltrating lymphocytes showed increased proliferation and markers of cytotoxicity in CD8(+) and CD4(+) T cells, reduced CD8(+) T-cell exhaustion, and decreased proportion of regulatory CD4(+) T cells in tumors of mice receiving TCRbeta-IL-2 followed by anti-PD-1. Diversification of the immune response with increased number of multifunctional, neoantigen-specific T cells was observed in mice receiving anti-TCRbeta-IL-2 followed by anti-PD-1, compared to each of the monotherapies. CONCLUSIONS: A novel T-cell activation mechanism sensitizes refractory tumors to ICI via T-cell function revival and epitope spreading. From these results, a clinical trial is planned to evaluate the combination of an anti-TCRbeta-IL-2 agent (invikafusp alfa) and anti-PD-1 in ICI-refractory non-small cell lung and castration-resistant metastatic prostate cancers.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.